Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 3214Carcinoma, Non-Small-Cell Lung 2727Breast Neoplasms 2550Colorectal Neoplasms 1461Prostatic Neoplasms 1307Neoplasm Metastasis 1300Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 944Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 832Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 472Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 435Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

pembrolizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ataxia Telangiectasia × Clear all
NCT07371663 2026-01-28

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Beijing Tide Pharmaceutical Co., Ltd

Phase 1/2 Recruiting
266 enrolled
DermatologicGastrointestinalGynecologicThoracic

Ataxia Telangiectasia, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Endometrial Neoplasms

NCT04095273 2024-04-02

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Bayer

Phase 1 Completed
56 enrolled

Ataxia Telangiectasia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡